Cypherpunk Technologies Inc.
CYPH
NASDAQ·Financial Services·Asset Management·Mkt cap $257.6M
$2.42
▲ +6.61%
P/E
3.84
Mkt Cap
$257.6M
52-Wk Range
$0.27–$3.70
52-Week Range
$0.27 - $3.70
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 746.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary monoclonal antibody technology targeting novel cancer pathways
- Strategic partnerships with established biotech leaders (BeiGene, Adimab)
- Multiple clinical-stage assets addressing underserved cancer indications
- Exclusive commercialization rights in Asia-Pacific region
Bear Case
1 risk
- Low volatility (beta 0.1).
Growth
Profitability at risk
Clinical trial milestones and regulatory approvals for DKN-01
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+241.7% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying CYPH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 12, 2026
Reported EPS of $0.18 vs -$0.03 consensus (+700.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+700.0%
Revenue trend · last 8Q
—
—
—
—
—
-100%
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$234.0K
$0
$0
$209.0K
$0
$0
$0
Margins · last 8Q
Profit
—
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · Jul 1, 2026
vs Industry
How CYPH stacks vs Asset Management
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related